Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;96(3):e29547.
doi: 10.1002/jmv.29547.

Optimization of a DNA-launched SARS-CoV-2 replicon with RNA splicing inhibitor Isoginkgetin

Hu Zhang  1   2 , Haitao Guo  1   2
Affiliations

Optimization of a DNA-launched SARS-CoV-2 replicon with RNA splicing inhibitor Isoginkgetin

Hu Zhang et al. J Med Virol. 2024 Mar.

Abstract

We have previously developed a bacterial artificial chromosome (BAC)-vectored SARS-CoV-2 replicon, namely BAC-CoV2-Rep, which, upon transfection into host cells, serves as a transcription template for SARS-CoV-2 replicon mRNA to initiate replicon replication and produce nanoluciferase (Nluc) reporter from the subgenomic viral mRNA. However, an inherent issue of such DNA-launched replicon system is that the nascent full-length replicon transcript undergoes process by host RNA splicing machinery, which reduces replicon replication and generates spliced mRNA species expressing NLuc reporter independent of replicon replication. To mitigate this problem, we employed Isoginkgetin, a universal eukaryotic host splicing inhibitor, to treat cells transfected with BAC-CoV2-Rep. Isoginkgetin effectively increased the level of full-length replicon transcripts while concurrently reducing the level of Nluc signal derived from spliced replicon mRNA, making the Nluc reporter signal more correlated with replicon replication, as evidenced by treatment with known SARS-CoV-2 replication inhibitors including Remdesivir, GC376, and EIDD-1931. Thus, our study emphasizes that host RNA splicing is a confounding factor for DNA-launched SARS-CoV-2 replicon systems, which can be mitigated by Isoginkgetin treatment.

Keywords: BAC; Isoginkgetin; SARS‐CoV‐2; mRNA splicing; replicon.

PubMed Disclaimer

References

REFERENCES

    1. Kurhade C, Xie X, Shi PY. Reverse genetic systems of SARS‐CoV‐2 for antiviral research. Antiviral Res. 2023;210:105486.
    1. Zhang H, Fischer DK, Shuda M, et al. Construction and characterization of two SARS‐CoV‐2 minigenome replicon systems. J Med Virol. 2022;94(6):2438‐2452.
    1. Takazawa S, Kotaki T, Nakamura S, Utsubo C, Kameoka M. Construction of Fosmid‐based SARS‐CoV‐2 replicons for antiviral drug screening and replication analyses in biosafety level 2 facilities. Virus Res. 2023;334:199176.
    1. Tanaka T, Saito A, Suzuki T, et al. Establishment of a stable SARS‐CoV‐2 replicon system for application in high‐throughput screening. Antiviral Res. 2022;199:105268.
    1. Zhang Y, Song W, Chen S, Yuan Z, Yi Z. A bacterial artificial chromosome (BAC)‐vectored noninfectious replicon of SARS‐CoV‐2. Antiviral Res. 2021;185:104974.

Publication types

LinkOut - more resources